Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902963 | 0.93 | BPTF (0.64) | BPTFHTR1AHTR1DHTR2AHTR7 | |
| SCHEMBL82373 | 0.93 | BPTF (0.64) | BPTFHTR1AHTR1DHTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL29903032 | 0.92 | BPTF (0.62) | BPTFHTR1AHTR1DHTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL20339255 | 0.92 | BPTF (0.62) | BPTFHTR1AHTR1DHTR2AHTR7 | |
| SCHEMBL806544 | 0.84 | CNR2 (0.59) | BPTFHTR1AHTR2AHTR7CNR2 | |
| SCHEMBL31415358 | 0.84 | CNR2 (0.59) | BPTFHTR1AHTR2AHTR7CNR2 | |
| SCHEMBL11988476 | 0.84 | GRIN2D (0.56) | BPTFHTR1AHTR2AHTR7CNR2 | |
| SCHEMBL1108644 | 0.83 | CNR2 (0.62) | HTR1AHTR2AHTR7CNR2GRIN2D | |
| SCHEMBL82447 | 0.83 | CNR2 (0.62) | HTR1AHTR2AHTR7CNR2GRIN2D | |
| SCHEMBL18768735 | 0.81 | CHRNB2 (0.51) | BPTFHTR2ACHRNB2CHRNA4PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-4201936-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-20220348577-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LLC (US) | 2022-11-03 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10155761-B2 | CXCR4 receptor antagonists | PROXIMAGEN, LLC (US) | 2018-12-18 | — | — | US | disclosed |
| EP-2927224-B1 | Receptor antagonists | PROXIMAGEN LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | BPTF 4147/4885HTR1A 67/4885HTR1D 119/4885 |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | BPTF 3701/4885HTR1A 46/4885HTR1D 83/4885 |
| US-20220348577-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | BPTF 2521/4885HTR1A 388/4885HTR1D 332/4885 |
| US-10155761-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | BPTF 2521/4885HTR1A 388/4885HTR1D 332/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | BPTF 4010/4885HTR1A 2226/4885HTR1D 2299/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | BPTF 3701/4885HTR1A 46/4885HTR1D 83/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | BPTF 2521/4885HTR1A 388/4885HTR1D 332/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | BPTF 1207/4885HTR1A 3061/4885HTR1D 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.